2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children

Dupuis, L. Lee; Sung, Lillian; Molassiotis, Alex; Orsey, Andrea; Tissing, Wim J. E.; Wetering, M. D. van de

doi:10.1007/s00520-016-3384-y

Cited by 81 publications

(121 citation statements)

References 41 publications

Supporting

Mentioning

120

Contrasting

Order By: Relevance

“…In adult patients, female sex has been reported to be a risk factor for CINV . In pediatric patients, however, the influence of sex and other factors on the risk of CINV has yet to be conclusively determined . The present results suggest that female sex may not constitute a risk factor for CINV in pediatric patients.…”

Section: Discussioncontrasting

confidence: 46%

“…Recommendations for the prevention of CINV in pediatric patients with cancer have been updated . The guidelines recommend that aprepitant be used for pediatric patients receiving HEC or MEC.…”

Section: Discussionmentioning

confidence: 99%

“…The current standard treatment for CINV in children and adolescents on highly emetogenic chemotherapy (HEC) includes a 5‐hydroxytryptamine‐3 receptor antagonist (5‐HT 3 RA), dexamethasone, and the neurokinin 1 receptor antagonist (NK 1 RA), aprepitant . For moderately emetogenic chemotherapy (MEC), and when dexamethasone cannot be used in pediatric patients, anti‐emetic therapy consists of a two‐drug combination of a 5‐HT 3 RA and aprepitant …”

mentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of aprepitant and fosaprepitant in pediatric patients

Saito

Kumamoto²,

Arima

et al. 2019

Pediatrics International

View full text Add to dashboard Cite

Background Single‐dose i.v. fosaprepitant has been approved as an alternative to 3 day oral aprepitant, a neurokinin‐1 receptor antagonist, and improves prevention of chemotherapy‐induced nausea and vomiting (CINV). Because fosaprepitant has shown similar efficacy to aprepitant in adult patients only, this study compared the efficacy and safety of aprepitant and fosaprepitant in pediatric patients. Methods Children younger than 18 years who received aprepitant or fosaprepitant to manage CINV between January 2015 and March 2018 at the National Cancer Center Hospital (Tokyo) were recruited to this study. The primary endpoint was complete response (CR; no vomiting/rescue medication) between 0 and 120 h after the start of chemotherapy. Secondary endpoints were safety based on the frequency of severe adverse events, and evaluation of patient characteristics as risk factors (effect of age and sex). Results A total of 125 chemotherapy cycles were evaluated. In the aprepitant group, CR was observed in 36 of 80 treatment cycles (45.0%), whereas in the fosaprepitant group, it was observed in 19 of 45 cycles (42.2%; P = 0.852). No treatment‐related severe adverse events were observed in either group. The number of non‐CR was greater than that of CR in patients aged 6–14 years. The difference in CR rate between male and female patients was not statistically significant (47.1% vs 40.0%, respectively; P = 0.471). Conclusions Aprepitant and fosaprepitant were safely used and may be equally useful for pediatric patients receiving highly emetogenic chemotherapy. CR rate may be associated with patient age.

show abstract

Section: Discussioncontrasting

confidence: 46%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of aprepitant and fosaprepitant in pediatric patients

Saito

Kumamoto²,

Arima

et al. 2019

Pediatrics International

View full text Add to dashboard Cite

show abstract

“…Chemotherapy‐induced nausea and vomiting (CINV) remain clinically important treatment‐related adverse effects for children and adolescents with cancer. For chemotherapy‐naïve pediatric patients, the inherent emetogenicity of the chemotherapy about to be administered remains the most important determinant of CINV and, therefore, of the CINV prophylaxis recommended in modern guidelines …”

Section: Introductionmentioning

confidence: 99%

Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline

Sing

Robinson

Flank

et al. 2019

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

This clinical practice guideline (CPG) provides clinicians with recommendations regarding chemotherapy emetogenicity classification in pediatric oncology patients. This information is critically important for the appropriate selection of antiemetic prophylaxis. Recommendations are based on a systematic review limited to pediatric patients and a framework for classification when antiemetic prophylaxis is provided. Findings of 87 publications informed the emetogenicity classification of 49 single‐agent and 13 combination‐agent regimens. Information required for the classification of many chemotherapies commonly administered to pediatric patients is lacking. In the absence of pediatric data, consultation of methodologically sound CPGs aimed at adult oncology patients may be appropriate.

show abstract

“…Based on this physiological rationale, the association of three drugs that antagonize the aforementioned biological mediators is considered a strategy to prevent CINV: 5‐HT 3 antagonists are known to significantly reduce acute CINV ; Aprepitant, a neurokinin 1 receptor (NK) antagonist, is associated with improved rates of complete response (absence of CINV and need for medication rescues) ; Corticosteroids are the oldest agents used to reduce acute and delayed nausea and vomiting. Although its mechanism of action on CINV prophylaxis is still undetermined, the association with 5‐HT 3 antagonists has demonstrated important CINV risk reduction . …”

Section: Introductionmentioning

confidence: 99%

Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta‐analyses of randomized controlled trials

Okumura

Rodrigues

Ferreira

et al. 2017

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children

Abstract: The findings of several randomized trials were used to update recommendations for the prevention of acute CINV. However, significant research gaps remain and must be addressed before CINV control in children can be optimized.

Cited by 81 publications

References 41 publications

Evaluation of aprepitant and fosaprepitant in pediatric patients

Evaluation of aprepitant and fosaprepitant in pediatric patients

Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline

Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta‐analyses of randomized controlled trials

Contact Info

Product

Resources

About